Skip to content

Insulet PODD Work in process

Work in process at other companies

Abbott logo
AbbottABT
$994M+11.7%
Eli Lilly logo
Eli LillyLLY
Medtronic logo
MedtronicMDT
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:InventoryWorkInProcess.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's work in process.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's work in process?
Insulet (PODD) reported work in process of $77.9M in Q1 2026.
How has Insulet's work in process changed year-over-year?
Insulet's work in process increased by 25.2% year-over-year, from $62.2M to $77.9M.
What is the long-term trend for Insulet's work in process?
Over 5 years (2020 to 2025), Insulet's work in process has grown at a 1.6% compound annual growth rate (CAGR), from $59.6M to $64.6M.